Stocktoria
CSL Limited CSL.AX
AU · Australian Securities Exchange · XASX · stock · Healthcare · website
CSL Limited financials (annual)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | $15.7B | $15.4B | $14.7B | $13.2B |
| Gross profit | $8.0B | $8.0B | $7.6B | $6.7B |
| R&D expense | $1.2B | $1.4B | $1.4B | $1.2B |
| SG&A expense | $2.6B | $2.6B | $2.4B | $2.5B |
| Operating income | $3.1B | $3.0B | $2.8B | $2.1B |
| Interest expense | $382.0M | $393.0M | $420.0M | $408.0M |
| Income tax | -$1.1B | $588.0M | $661.0M | $419.0M |
| Net income | -$2.6B | $3.0B | $2.6B | $2.2B |
| EPS (diluted) | $-5.35 | $6.17 | $5.45 | $4.53 |
| Cash & equivalents | $1.5B | $2.2B | $1.7B | $1.5B |
| Inventory | $6.6B | $6.5B | $6.0B | $5.5B |
| Goodwill | $6.4B | $8.1B | $8.1B | $8.1B |
| Total assets | $33.6B | $39.4B | $38.0B | $36.2B |
| Total debt | $10.9B | $11.5B | $12.2B | $12.2B |
| Total liabilities | $17.3B | $18.0B | $18.6B | $18.4B |
| Shareholders' equity | $14.8B | $19.3B | $17.4B | $15.8B |
| Share buybacks | $724.0M | — | — | — |
Growth · year-over-year · Revenue CAGR 6%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | +1.7% | +5.0% | +11.5% | — |
| Net income growth | -185.9% | +13.6% | +20.4% | — |
| EPS growth | -186.7% | +13.2% | +20.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · AU · as of 2026-06-30. Figures in USD. Facts plus Stocktoria's own computed scores — not investment advice.